Abstract: A driving support ECU 10 determine that a mistaken acceleration operation condition is satisfied when a time from a first time point to a second time point is equal to or shorter than a predetermined threshold time (T2th), while a shift position is at a reverse position (R) for driving the vehicle backward. The first time point is a time point at which the driver does not operate the brake operation member. The second time point is a time point at which an index value corresponding to an acceleration operation amount satisfies a predetermined index value condition to be satisfied when the driver performs a predetermined sudden operation of the acceleration operation member. The driving support ECU make the driving force when the mistaken acceleration operation condition is satisfied smaller than the driving force when the mistaken acceleration operation condition is not satisfied.

Abstract: A patch includes an adhesive layer and a release liner laminated on at least one surface of a backing. The adhesive layer comprises, as an adhesive base agent, at least one selected from the group consisting of acrylate-based adhesives and rubber-based adhesives, and the adhesive layer comprises 0.3 to 5% by mass of a nonfunctional silicone oil having a kinematic viscosity of 10 to 350 cSt at 25° C.

Abstract: The present invention is a patch comprising a support, and an adhesive layer disposed on at least one surface of the support and formed of an adhesive composition comprising a drug and an adhesive, wherein the drug is cytisine or a salt thereof, and the adhesive composition has an acid value of 10 or less.

Abstract: A warning output device includes a rear sensor unit and an electronic control unit. The electronic control unit is configured to, when a shift position is an R range, based on information from the sensor unit indicating that a first obstacle is detected, output a warning for informing an occupant of the presence of the first obstacle, in a first state, output first predetermined warning display and first predetermined warning sound; and in a second state, output second predetermined warning display and second predetermined warning sound. The ECU is configured to, in the second state, output the second predetermined warning sound for a predetermined time, then stop the output of the second predetermined warning sound, and output the second predetermined warning display for a longer time than the second predetermined warning sound.

Abstract: A patch includes an adhesive layer and a release liner laminated on at least one surface of a backing. The adhesive layer comprises, as an adhesive base agent, at least one selected from the group consisting of acrylate-based adhesives and rubber-based adhesives, and the adhesive layer comprises 0.3 to 5% by mass of a nonfunctional silicone oil having a kinematic viscosity of 10 to 350 cSt at 25° C.

Abstract: A ropinirole-containing patch comprises an adhesive agent layer and a support layer, the adhesive agent layer containing ropinirole and/or a pharmaceutically acceptable salt thereof, wherein a content of the ropinirole and/or the pharmaceutically acceptable salt thereof in terms of free ropinirole in the adhesive agent layer satisfies the following two conditions: 5 to 13.2% by mass relative to a total mass of the adhesive agent layer, and 0.12 to 2.7 mg/cm2 per unit area of the adhesive agent layer.

Abstract: A patch comprising a support layer and an adhesive agent layer, wherein the adhesive agent layer comprises at least one drug selected from the group consisting of emedastine and pharmaceutically acceptable salts thereof, at least one adhesive agent selected from the group consisting of rubber-based adhesive agents and silicone-based adhesive agents, and an alkali metal fumarate as a cohesive force-improving agent for the adhesive agent layer.

Abstract: The present invention is a patch comprising a support, and an adhesive layer disposed on at least one surface of the support and formed of an adhesive composition comprising a drug and an adhesive, wherein the drug is cytisine or a salt thereof, and the adhesive composition has an acid value of 10 or less.

Abstract: The present invention relates to a transdermal preparation having a backing and an adhesive layer laminated on the backing, wherein the adhesive layer contains 4-ethylene-2(3H)-indolone and a physiologically active compound, and wherein the 4-ethylene-2(3H)-indolone is present in an amount from 0.001 to 4 mass % of the total mass of components of the adhesive layer.

Abstract: A ropinirole-containing patch comprises an adhesive agent layer and a support layer, the adhesive agent layer containing ropinirole and/or a pharmaceutically acceptable salt thereof, wherein a content of the ropinirole and/or the pharmaceutically acceptable salt thereof in terms of free ropinirole in the adhesive agent layer is 5 to 13.2% by mass relative to a total mass of the adhesive agent layer.

Abstract: A patch comprising a support layer and an adhesive agent layer, wherein the adhesive agent layer comprises at least one drug selected from the group consisting of emedastine and pharmaceutically acceptable salts thereof, at least one adhesive agent selected from the group consisting of rubber-based adhesive agents and silicone-based adhesive agents, and an alkali metal fumarate as a cohesive force-improving agent for the adhesive agent layer.

Abstract: A ropinirole-containing patch comprises an adhesive agent layer and a support layer, the adhesive agent layer containing ropinirole and/or a pharmaceutically acceptable salt thereof, wherein a content of the ropinirole and/or the pharmaceutically acceptable salt thereof in terms of free ropinirole in the adhesive agent layer satisfies the following two conditions: 5 to 13.2% by mass relative to a total mass of the adhesive agent layer, and 0.12 to 2.7 mg/cm2 per unit area of the adhesive agent layer.

Abstract: A ropinirole-containing patch comprises an adhesive agent layer and a support layer, the adhesive agent layer containing ropinirole and/or a pharmaceutically acceptable salt thereof, wherein a content of the ropinirole and/or the pharmaceutically acceptable salt thereof in terms of free ropinirole in the adhesive agent layer is 5 to 13.2% by mass relative to a total mass of the adhesive agent layer.

Abstract: The present invention relates to an adhesive patch-containing package bag 1, having: a package bag 8; and an adhesive patch 10 stored inside the package bag 8, wherein the adhesive patch 10 has a backing 12, an adhesive layer 14 laminated on at least one side of the backing 12 and containing ropinirole and/or a pharmaceutically acceptable salt thereof, and a release liner 16 covering the adhesive layer 14, and a relative humidity at 4° C. is maintained at 35% or higher inside the package bag 8.

Abstract: The present invention relates to a transdermal preparation having a backing and an adhesive layer laminated on the backing, wherein the adhesive layer contains 4E indolone and a physiologically active compound.